Nurix reports positive Phase 1 data for BTK degraders NX-5948 and NX-2127 at ASH 2023

Nurix Therapeutics, Inc.

NX-5948: 3 partial responses in CLL (n=7); no DLTs or treatment-related SAEs across 50-450 mg doses.
NX-2127: 2 complete responses in NHL (MCL, DLBCL); 40.7% ORR in CLL (n=27), up from 33% at ASH 2022.
NX-2127 safety manageable: neutropenia dose-related, atrial fibrillation 11.1% (down from 17% prior).
Dose escalation continues for both programs; more data expected in 2024.
Company plans to develop NX-5948 broadly in CLL and other NHL indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.